Cytokinetics Incorporated has granted stock options and restricted stock units (RSUs) as part of new compensation agreements for recent hires. Jeffrey Hessekiel, the company's new Executive Vice President, Chief Legal and Administrative Officer, received 87,297 RSUs, which will vest over three years with 40% vesting on the first and second anniversaries of the grant date, and the remaining 20% on the third anniversary, contingent on continued employment. Three additional employees hired in October and November 2025 were granted stock options to purchase a total of 13,175 shares at $66.44 per share and 8,881 RSUs, also vesting over three years for the RSUs and four years for the stock options. The stock options have a 10-year term.